ALIGOS THERAPEUTICS / EMORY UNIVERSITY LICENSE AGREEMENT OF JUNE 26, 2018License Agreement • September 25th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This License Agreement (the “Agreement”) is entered into and made effective as of June 26, 2018, (the “Effective Date”) by and between Emory University ( “Emory”), a Georgia nonprofit corporation with offices at 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322, and Aligos Therapeutics, Inc. (“Aligos”), a Delaware corporation having its principal offices at 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080.
LICENSE AGREEMENTLicense Agreement • September 25th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This License Agreement (the “Agreement”) is entered into and made effective as of December 19, 2018, (the “Effective Date”) by and between Luxna Biotech Co., Ltd. (“Luxna”), a Japanese corporation having its principal place of business at 3-21-1 Onoharanishi, Mino-City, Osaka 562-0032 Japan, and Aligos Therapeutics, Inc. (“Aligos”), a Delaware corporation having its principal offices at 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080.
SUMMARY OF BASIC LEASE INFORMATIONLease • September 25th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
AMENDMENTAligos Therapeutics, Inc. • September 25th, 2020 • Biological products, (no disgnostic substances)
Luxna Biotech Co., Ltd. (“Luxna”) and Aligos Therapeutics, Inc. (“Aligos”) agree to amend their License Agreement dated as of December 19, 2018 (“License Agreement”), as follows:
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • September 25th, 2020 • Aligos Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment (the “First Amendment”), effective as of June 18, 2020 (“Effective Date”), is entered into between Emory University (“Emory”), a Georgia nonprofit corporation with offices at 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322, and Aligos Therapeutics, Inc. (“Aligos”), a Delaware corporation having its principal offices at 156 2nd Street, Suite 403, San Francisco, California 94105 (each individually a “Party” and collectively the “Parties”), and amends that certain Aligos Therapeutics / Emory University License Agreement of June 26, 2018 between the Parties (the “License Agreement”). Capitalized terms used herein without definition shall have the meaning set forth in the License Agreement.
